secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0000950170-23-008146
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports FY22 net loss of $107.5M; cash runway into H1 2025; pipeline advances
--------------------------------------------------------------------------------

- Net loss $107.5M in 2022 (vs $71.3M in 2021); revenue $3.1M (vs $18.0M) due to Roche collaboration end.
- Cash, equivalents & marketable securities $218.5M; expected to fund operations into first half 2025.
- 4D-150 wet AMD interim data: >90% reduction in anti-VEGF injections; dose exploration enrolled, phase 2 dose expansion started Jan 2023. DME IND cleared.
- 4D-710 cystic fibrosis: cohort 2 enrollment completed Feb 2023; interim data planned for Q2 2023 conference.
- 4D-310 Fabry cardiomyopathy: interim cardiac improvements shown; FDA clinical hold response expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023008146/0000950170-23-008146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023008146/fdmt-20230315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer